Last €77.31 EUR
Change Today +0.49 / 0.64%
Volume 445.3K
SAN On Other Exchanges
Symbol
Exchange
EN Paris
EN Paris
New York
OTC US
BrsaItaliana
Mexico
Frankfurt
Frankfurt
NASDAQ GM
As of 7:19 AM 07/30/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Gerard Van Kemmel

Independent Director, Chairman of Compensation Committee, Member of Audit Committee and Member of Appointments & Governance Committee, Sanofi
AgeTotal Calculated CompensationThis person is connected to 17 board members in 1 different organizations across 4 different industries.

See Board Relationships
75€142,500

Background*

Mr. Gerard Van Kemmel served as the Chief Operating Officer and Executive Vice President at Cambridge Technology Partners (Massachusetts), Inc. since June 1999 until July 2001. Mr. Van Kemmel served as the Cambridge Technology Partners Massachusetts Inc.'s Senior Vice President, Cambridge Management Consulting from November 1997 to June 1999. He joined Cambridge in November 1997 in connection with Cambridge’s acquisition of Peter Chadwick Holdings Limited. He joined ...

Read Full Background

Corporate Headquarters*

54, Rue La Boétie
Paris, Ile-de-France 75008

France

Phone: 33 1 53 77 40 00
Fax: --

Board Members Memberships*

Former Director and Member of Audit Committee
Former Director
2003-Present
Independent Director, Chairman of Compensation Committee, Member of Audit Committee and Member of Appointments & Governance Committee

Education*

MBA
Stanford Graduate School of Business
Unknown/Other Education
Ecole des Hautes Etudes Commerciales de Montreal
Unknown/Other Education
Groupe HEC

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

There is no Stock Options data available.

Total Compensation*

Total Annual Cash Compensation€142,500
Total Calculated Compensation€142,500
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SAN:FP €77.31 EUR +0.49

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
John C. Martin Ph.D.Chairman and Chief Executive Officer
Gilead Sciences Inc.
$1.6M
Marijn E. Dekkers Ph.D.Chairman of Management Board and Chief Executive Officer
Bayer AG
€2.9M
Andrew Philip Witty Chief Executive Officer, Executive Director, Member of Corporate Administration & Transactions Committee and Member of Finance Committee
GlaxoSmithKline plc
2.9M GBP
Kenneth C. Frazier Chairman and Chief Executive Officer
Merck & Co. Inc.
$1.5M
Lars Rebien Sørensen Chief Executive Officer
Novo Nordisk A/S
kr15.2M
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANOFI, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.